Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects

BMC Neurol. 2015 Oct 6:15:182. doi: 10.1186/s12883-015-0449-3.

Abstract

Background: Dysferlin is reduced in patients with limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal anterior compartment myopathy, and in certain Ethnic clusters.

Methods: We evaluated clinical and genetic patient data from three different Swiss Neuromuscular Centers.

Results: Thirteen patients from 6 non-related families were included. Age of onset was 18.8 ± 4.3 years. In all patients, diallelic disease-causing mutations were identified in the DYSF gene. Nine patients from 3 non-related families from Central Switzerland carried the identical homozygous mutation, c.3031 + 2 T>C. A possible founder effect was confirmed by haplotype analysis. Three patients from two different families carried the heterozygous mutation, c.1064_1065delAA. Two novel mutations were identified (c.2869 C>T (p.Gln957Stop), c.5928 G>A (p.Trp1976Stop)).

Conclusions: Our study confirms the phenotypic heterogeneity associated with DYSF mutations. Two mutations (c.3031 + 2 T>C, c.1064_1065delAA) appear common in Switzerland. Haplotype analysis performed on one case (c. 3031 + 2 T>C) suggested a possible founder effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Dysferlin
  • Female
  • Founder Effect*
  • Heterozygote
  • Homozygote
  • Humans
  • Male
  • Membrane Proteins / genetics*
  • Middle Aged
  • Muscle Proteins / genetics*
  • Muscular Dystrophies, Limb-Girdle / genetics*
  • Mutation*
  • Phenotype
  • Switzerland
  • Young Adult

Substances

  • DYSF protein, human
  • Dysferlin
  • Membrane Proteins
  • Muscle Proteins

Supplementary concepts

  • Dysferlinopathy